No Data
Sichuan Kelun Pharmaceutical (002422.SZ): Chloride Verapamil Emulsion Injection has received Pharmaceutical registration approval.
On January 2, Glonghui reported that Sichuan Kelun Pharmaceutical (002422.SZ) announced the company's Chemical Drug "Amlodipine Lactate Injection" has recently received drug registration approval from the National Medical Products Administration. Amlodipine Lactate Injection is a rapidly acting calcium channel blocker developed by AstraZeneca, which was first launched in the USA in 2008 for the treatment of hypertension in patients who are not suitable for oral administration or where the effectiveness of oral medications is suboptimal. Amlodipine is a rapid-acting intravenous antihypertensive drug that acts faster than the commonly used standard treatment medication nicardipine, allowing for quick and precise real-time adjustment of blood pressure, and is more suitable for patients with liver and kidney dysfunction as well as elderly patients.
Sichuan Kelun Pharmaceutical Unit Secures Approval for Tagolizumab Antibody
Sichuan Kelun Pharmaceutical (002422.SZ): Subsidiary anti-PD-L1 tagolizumab has been approved for listing by the National Medical Products Administration.
Sichuan Kelun Pharmaceutical (002422.SZ) announced that the company's holding subsidiary Sichuan Kelun Bo Tai Biomedical...
Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet
Sichuan Kelun Pharmaceutical (002422.SZ): The employee stock ownership plan shares were sold out in 2022.
On December 19, Gelonghui reported that Sichuan Kelun Pharmaceutical (002422.SZ) announced that on October 25, 2024, the company received the "Securities Transfer Registration Confirmation" issued by the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited. The non-trade transfer of stocks that met the unlocking conditions for the second unlocking period of the 2022 employee stock ownership plan has been completed, with a total of 1.502 million shares transferred, accounting for 0.0938% of the company's total equity at that time. The stocks held in this employee stock ownership plan account, except for the aforementioned 3.008 million shares that were non-trade transferred to the holder's securities account that met the unlocking conditions.
Sichuan Kelun Pharmaceutical (002422.SZ): Some products are planned to be awarded in centralized procurement.
On December 13, Gelonghui reported that Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) announced that on December 12, 2024, it and its subsidiaries participated in the bidding organized by the Joint Procurement Office for the tenth batch of national centralized procurement of Pharmaceuticals. The company's products are expected to win the bidding for this centralized procurement.
Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E
